“…Neoadjuvant trastuzumab with or without lapatinib shows pCR rates of 50–70% in HER2-enriched tumors, 9–34% in luminal A, 17–36% in luminal B, and 25–38% in basal-like cases (12, 25, 27). Similarly, pCR rates by intrinsic subtype in patients treated with neoadjuvant pertuzumab plus trastuzumab were 70–83% in the HER2-enriched subtype, 16–45% in luminal A, 16–52% in luminal B, and 20–85% in basal-like tumors (13, 17, 22, 23). In a series of patients with BluePrint-defined subtypes, the pCR rate was 76% in the HER2+ type, 31% in the luminal type, and 43% in the basal type (28).…”